Mourabit Halima, Author at MediaMedic

Exercise Interventions for Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review

By Mourabit Halima 2025.02.26

Editor’s Note: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children aged 2 to 19, affecting approximately 1 in 10 children. Recently, a research…

Nanjing Drum Tower Hospital Team Unveils the Virological and Immunological Characteristics of HBeAg-Positive Chronic Hepatitis B Patients with Low HBs

By Mourabit Halima 2025.02.26

Editor’s Note: Chronic hepatitis B (CHB) remains a major global health challenge, causing over 820,000 deaths annually, primarily due to virus-related liver cirrhosis and hepatocellular carcinoma (HCC). Throughout different stages…

ASCO GU 2025 | Dr. Kan Gong & Dr. Eric Jonasch Discuss New Strategies and Future Perspectives in Kidney Cancer Treatment (Part II)

By Mourabit Halima 2025.02.26

Clear cell renal cell carcinoma (ccRCC) is closely associated with dysregulation of the VHL pathway, leading to the overexpression of HIF-2α and activation of multiple oncogenic pathways. Targeting HIF-2α with therapies such as belzutifan has provided new hope for patients with VHL syndrome and even broader applications in kidney cancer treatment. At this year’s ASCO Genitourinary Cancers Symposium (ASCO GU), Urology Frontier invited Dr. Kan Gong from Peking University First Hospital to discuss with Dr. Eric Jonasch, Director of the VHL Clinical Center at MD Anderson Cancer Center, the patient populations benefiting from belzutifan, management of adverse effects, and its future clinical applications.

KEYNOTE-522: Pembrolizumab Improves Event-Free Survival in Early-Stage TNBC

By Mourabit Halima 2025.02.26

The KEYNOTE-522 trial, published in May 2024, highlights how pembrolizumab combined with chemotherapy improves event-free survival (EFS) in early-stage triple-negative breast cancer (TNBC), particularly across Residual Cancer Burden (RCB) categories.…

The RIGHT Choice Trial: Ribociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

By Mourabit Halima 2025.02.26

The RIGHT Choice trial, published in August 2024, evaluated the efficacy of ribociclib plus endocrine therapy (ET) versus combination chemotherapy (CT) as a first-line treatment in premenopausal women with clinically…

Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine

By Mourabit Halima 2025.02.26

Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine. This large-scale, nationwide cohort study across Denmark, Finland, Norway, and Sweden found that children who received MMR after the diphtheria-tetanus-acellular pertussis (DTaP) vaccine had lower rates of infectious disease hospitalizations, suggesting potential non-specific protective effects beyond its targeted diseases.

Dr. Petek Eylül Taneri, MD, PhD has led a landmark study published in JAMA Network Open

By Mourabit Halima 2025.02.26

Dr. Petek Eylül Taneri, MD, PhD has led a landmark study published in JAMA Network Open, setting a new standard for neonatal sepsis research. The Neonatal Sepsis Core Outcome Set (NESCOS) is a global consensus that defines the key outcomes to be measured in all future studies on neonatal sepsis, ensuring consistency, comparability, and impact.

Advancing Treatment for Metastatic Triple-Negative Breast Cancer: Dr. Aditya Bardia’s Work in the ASCENT Trial

By Mourabit Halima 2025.02.26

On May 20, 2024, Dr. Aditya Bardia and his colleagues published the final results of the Phase III ASCENT trial, reinforcing Sacituzumab Govitecan (SG) as a superior treatment option over…

Annual Review | Dr. Ou Bai: Focusing on Advances and Challenges in PTCL Diagnosis and Treatment in 2024

By Mourabit Halima 2025.02.25

In recent years, the field of hematologic oncology has seen numerous encouraging breakthroughs, with Chinese scholars increasingly contributing to research in cell therapy, significantly advancing the development of both the discipline and clinical practice. Hematology Frontier specially invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the progress in the diagnosis and treatment of peripheral T-cell lymphoma (PTCL) in 2024. Dr. Ou Bai shared the groundbreaking advancements in PTCL treatment this year, provided insights into the innovative explorations at their hospital, and offered a forward-looking perspective on new methods and drugs in PTCL therapy.

Dr. Zhanhong Chen: Exploring New Treatment Pathways for HR+ Advanced Breast Cancer – The Future Role of CDK4/6 Inhibitors and Novel Targeted Therapies

By Mourabit Halima 2025.02.25

In the evolving landscape of breast cancer treatment, the management of HR+ advanced breast cancer remains a central focus. During the Northern China Breast Cancer Salon – Annual Progress Review, Dr. Zhanhong Chen from Zhejiang Cancer Hospital delivered an in-depth analysis on the stratified treatment approach for HR+ advanced breast cancer. Following the meeting, Oncology Frontier invited Professor Chen to discuss key topics, including the optimal timing for CDK4/6 inhibitor use and the future development of novel targeted therapies.